Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

February 28, 2014

Conditions
Smoking Cessation
Interventions
DRUG

Ganaxolone

"Pre-Quit Period:~Beginning at Session P1, subjects will receive ganaxolone at a dose of 400mg total daily (200mg bid) for the first three days, 800mg total daily (400mg bid) for the next three days and 1200mg total daily (600mg bid) for the remainder of the first four weeks.~Post-Quit Period:~Following the quit-day, subjects will receive ganaxolone at a dose of (1200mg total daily) for the next week. Down-titration of ganaxolone will begin at post-quit week two. Subjects will receive ganaxolone at a dose of 800mg total daily (400mg bid) to take for three days and 400mg total daily (200mg bid) to take for three."

DRUG

Nicotine Patch

"Pre-Quit Period:~Beginning at Session P2, subjects will receive active 21mg/24h nicotine patches to apply daily for the next two weeks.~Post-Quit Period:~Following the quit-day, subjects will continue to apply active nicotine patches daily for the remainder of the study (21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week)."

Trial Locations (4)

27103

Duke Center for Smoking Cessation, Winston-Salem

27609

Duke Center for Smoking Cessation, Raleigh

27705

Duke Center for Smoking Cessation, Durham

28210

Duke Center for Smoking Cessation, Charlotte

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Jed E. Rose

OTHER

NCT01857531 - Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate | Biotech Hunter | Biotech Hunter